ReviewViruses2024
Mayaro Virus: An Emerging Alphavirus in the Americas.
Review in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Arbovirus co-circulation and epidemiological convergence in a changing climate: challenges for surveillance, diagnosis and public health preparedness.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Review
- Eugenol-Derived Piperazine Mannich Bases as Selective Inhibitors of Mayaro Virus: In Vitro Antiviral Evaluation and Mechanistic Insights.Journal of medical virology · 2026Article
- Evaluation of the Antiviral Activity of Monomeric, Dimeric, and Oligomeric Flavonoids against Chikungunya and Mayaro Viruses.ACS omega · 2026Article
- Productive Mayaro Virus Infection Requires Host Fatty Acid Synthase for nsP1 S-palmitoylation.bioRxiv : the preprint server for biology · 2026Article
- Discovery of Synthetic Imine-Chalcones Targeting Mayaro Virus Replication.Pathogens (Basel, Switzerland) · 2026Article
- Retrospective Phylogenetic Analysis of Mayaro Virus, French Guiana, 1996-2024.Emerging infectious diseases · 2026Article
- The Second Silent Pandemic: Why Arboviruses Demand an Orchestrated Global Health Response.Pathogens (Basel, Switzerland) · 2026Review
- Temporal cytokine profiling of acute dengue, Zika, Chikungunya, and Mayaro virus infections in Northern Peru.BMC infectious diseases · 2026Article
- Broad-spectrum antiviral activity of the synthetic rocaglate zotatifin against Mayaro virus and other viruses.Frontiers in cellular and infection microbiology · 2026Article
- Evaluation of Antiviral Activity ofACS omega · 2025Article
- Physiological Impacts on the Mosquito Vector Hosts Refine Vectorial Capacity Estimates of Mayaro Virus Transmission Risk.Viruses · 2025Article
- Proximity interactome of alphavirus replicase component nsP3 includes proviral host factors eIF4G and AHNAK.PLoS pathogens · 2025Article
- Neuropathogenesis of Old World Alphaviruses: Considerations for the Development of Medical Countermeasures.Viruses · 2025Review
- Proceedings from the Fourth Mesoamerican Symposium "Dr. Roberto Navarro López" on Emerging Zoonotic Disease and Arboviruses: Commenting Insights and Research Findings.Research and reports in tropical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Mayaro virus (MAYV) is an arbovirus first isolated in Trinidad and Tobago in 1954. MAYV is the causative agent of Mayaro fever, which is characterised by high fever, maculopapular rash, myalgia and arthralgia. The potential for chronic arthralgia is of particular clinical concern. Currently, MAYV outbreaks are restricted to South and Central America, with some cases reported in Africa as well as several imported cases in Europe. However, in recent years, MAYV has become a growing global concern due to its potential to emerge into urban transmission cycles. Challenges faced with diagnostics, as well as a lack of specific antivirals or licensed vaccines further exacerbate the potential global health threat posed by MAYV. In this review, we discuss this emerging arboviral threat with a particular focus on the current treatment and vaccine development efforts. Overall, MAYV remains a neglected arbovirus due to its limited area of transmission. However, with the potential of its urbanisation and expanding circulation, the threat MAYV poses to global health cannot be overlooked. Further research into the improvement of current diagnostics, as well as the development of efficacious antivirals and vaccines will be crucial to help prevent and manage potential MAYV outbreaks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.